Docetaxel Trihydrate: Brands, Price & Uses in Bangladesh

Docetaxel Trihydrate is a taxane-class chemotherapy agent used, under the supervision of an oncologist, for the treatment of several solid tumors. It is administered only by intravenous (IV) infusion in a hospital or oncology chemotherapy setting.

FDA-Approved / Established Indications

• Breast cancer: Locally advanced or metastatic breast cancer, as a single agent after failure of prior chemotherapy, or in combination with doxorubicin and cyclophosphamide as adjuvant therapy for operable node-positive breast cancer.
• Non-small cell lung cancer (NSCLC): Locally advanced or metastatic NSCLC, as a single agent after platinum-based chemotherapy failure, or in combination with cisplatin for chemotherapy-naive patients.
• Metastatic castration-resistant prostate cancer: In combination with prednisone.
• Advanced gastric adenocarcinoma: In combination with cisplatin and fluorouracil, in patients who have not received prior chemotherapy for advanced disease.
• Squamous cell carcinoma of the head and neck: In combination with cisplatin and fluorouracil, for induction treatment of locally advanced disease.

Docetaxel Trihydrate is always used as part of a physician-directed chemotherapy protocol; it is never self-administered or used outside the combination regimens specified above without medical supervision.

Docetaxel Trihydrate must be administered only by, or under the direct supervision of, a physician experienced in the use of cancer chemotherapeutic agents, in a facility equipped to manage severe hypersensitivity reactions. It is given strictly as an intravenous infusion over approximately 1 hour, every 3 weeks, using non-PVC infusion equipment. The exact dose, cycle length, and number of cycles are individualized by the treating oncologist based on indication, combination regimen, body surface area, and patient tolerance.

Mandatory Premedication

To reduce the risk of hypersensitivity reactions and severe fluid retention, all patients should be premedicated with an oral corticosteroid (e.g., dexamethasone 16 mg/day, such as 8 mg twice daily) for 3 days, starting 1 day before the Docetaxel Trihydrate infusion, unless contraindicated.

Indication-Based Dosing (as determined by the treating oncologist)

Dose adjustments or delays are required for neutropenia, febrile neutropenia, severe peripheral neuropathy, hepatic impairment, or other significant toxicity, as determined by the treating physician. See Precautions and Warnings and Use in Special Populations.

Adverse effects of Docetaxel Trihydrate are common and can be serious, requiring close medical monitoring throughout treatment.

Very Common

• Neutropenia, anemia, thrombocytopenia, febrile neutropenia and infections
• Hypersensitivity reactions (flushing, rash, itching, chest tightness, back pain, dyspnea, fever, chills)
• Peripheral neuropathy (numbness, tingling, pain), altered taste (dysgeusia)
• Fluid retention (edema, weight gain, pleural/pericardial effusion, ascites)
• Alopecia (hair loss), nail changes/disorders, skin reactions on hands and feet
• Nausea, vomiting, diarrhea, mucositis/stomatitis, constipation, anorexia
• Fatigue/asthenia, myalgia, arthralgia

Serious / Less Common

• Severe neutropenic sepsis and febrile neutropenia
• Severe hypersensitivity reactions including anaphylaxis
• Enterocolitis, neutropenic colitis, gastrointestinal perforation (rare, can be fatal)
• Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Fluid overload leading to cardiac or pulmonary complications
• Cardiac arrhythmias, heart failure (rare)
• Secondary malignancies (leukemia) with long-term use

Patients should seek immediate medical attention for fever, signs of infection, severe shortness of breath, chest pain, severe rash, or signs of an allergic reaction during or after a Docetaxel Trihydrate infusion.